Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma - FLASH

Study identifier:D7552C00001

ClinicalTrials.gov identifier:NCT05251259

EudraCT identifier:2021-003338-35

CTIS identifier:N/A

Recruiting

Official Title

A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Multiple Dose Levels of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults with Moderate to Severe Uncontrolled Asthma

Medical condition

asthma

Phase

Phase 2

Healthy volunteers

No

Study drug

Atuliflapon, Placebo

Sex

All

Estimated Enrollment

1102

Study type

Interventional

Age

18 Years - 80 Years

Date

Study Start Date: 27 Jan 2022
Estimated Primary Completion Date: 29 Jan 2025
Estimated Study Completion Date: 29 Jan 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria